Briganti et al. reported that timely administration of early salvage radiotherapy (given at PSA ≤0.5 ng/ml) was comparable to adjuvant radiotherapy for improving biochemical recurrence-free survival in pT3N0 prostate cancer, and suggested that initial observation followed by early salvage radiotherapy delivered at low PSA levels might be a viable option for the majority of surgically-managed patients with pT3N0 prostate cancer [19]. The gene discussed is KLK3; the disease is prostate carcinoma.